Company news
Monopar Therapeutics Inc. news in 2021
Monopar Therapeutics Inc.'s news releases, calls and decks from 2021, newest first.
Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial
December 7, 2021
Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments
November 11, 2021
Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma
October 26, 2021
Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma
September 15, 2021
Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe
September 12, 2021
Monopar Therapeutics to Present at Upcoming Investor Conferences in September
September 8, 2021
Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates
August 11, 2021
Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial
August 4, 2021
Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma
August 2, 2021
Monopar Appoints Octávio Costa, MD, as Chief Medical Officer
July 11, 2021
Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO
June 23, 2021
Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer
June 2, 2021
Monopar Therapeutics Expands Leadership Team with Appointment of Andrew Cittadine as Chief Operating Officer
May 31, 2021
Monopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic
May 25, 2021
Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery
May 23, 2021
Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates
May 12, 2021
Monopar’s uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study
March 29, 2021
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates
March 24, 2021
Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery
March 1, 2021
Monopar Therapeutics to Present at Upcoming Investor Conferences
February 23, 2021
Monopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical Operations
February 17, 2021
Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
February 15, 2021
Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer
February 10, 2021
Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada
February 8, 2021
Decks in 2021
- MASCC/ISOO Annual Meeting 2021
Conference · 18 slides · Jun 24, 2021